Immunovant, Inc.

Listed Company

IMVTCIK 0001764013NasdaqLarge AcceleratedBiological Products, (No Diagnostic Substances)DelawareFY ends Mar 31

Period

FY 2026

Revenue

—

Net Income

$-505.61M

Total Assets

$957.01M

Equity

$852.59M

Shares Out

205.31M

Op. Cash Flow

$-407.31M

IMVT$40.26+120.27% · past yearDBEQ Basic

Daily closing prices

Business

Immunovant, Inc. is a clinical-stage immunology company developing IMVT-1402, a monoclonal antibody that inhibits the neonatal Fc receptor (FcRn) to reduce pathogenic IgG antibodies in autoimmune diseases. The company is advancing potentially registrational trials of IMVT-1402 across six indications: Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, Sjögren's disease, and cutaneous lupus erythematosus. Immunovant is a majority-owned subsidiary of Roivant Sciences Ltd and operates through a collaborative development model leveraging the Roivant platform and external contract manufacturing partners.

Summary from 10-K filed 2026-05-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31
Research and development	457	361	213	160	102
Acquired in-process research and development	0	0	13	10	—
General and administrative	76	77	57	48	54
Total operating expenses	533	438	283	218	156
Interest income, net	−25	−25	−25	−8	—
Other (income) expense, net	−2	−471,000	1	253,000	781,000
Loss before provision for income taxes	−505	−413	−259	−211	−157
Provision for income taxes	200,000	891,000	567,000	9,000	−84,000
Net loss	−506	−414	−259	−211	−157
Net loss per common share basic (in dollars per share)	−2.77	−2.73	−1.88	−1.71	−1.43
Net loss per common share diluted (in dollars per share)	−2.77	−2.73	−1.88	−1.71	−1.43
Weighted average common shares outstanding basic (in shares)	182	152	138	123	110
Weighted average common shares outstanding diluted (in shares)	182	152	138	123	110

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31
Cash and cash equivalents	902	714	635	377	494
Accounts receivable	1	2	5	700,000	12
Prepaid expenses and other current assets	43	51	25	27	6
Income tax receivable	3	427,000	166,000	185,000	632,000
Total current assets	949	768	666	404	513
Operating lease right-of-use assets	72,000	98,000	133,000	1	2
Property and equipment, net	443,000	844,000	462,000	333,000	330,000
Other assets	8	8	0	—	—
Total assets	957	776	666	406	516
Accounts payable	8	18	7	1	19
Accrued expenses	97	51	41	40	25
Current portion of operating lease liabilities	72,000	98,000	138,000	1	1
Due to Roivant Sciences Ltd.	175,000	273,000	15,000	350,000	—
Total current liabilities	104	69	49	43	45
Total liabilities	104	69	49	43	46
Commitments and contingencies (Note 10)	—	—	—	—	—
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 203,940,353 shares issued and outstanding at March 31, 2026 and 500,000,000 shares authorized, 170,111,593 shares issued and outstanding at March 31, 2025	20,000	16,000	14,000	13,000	12,000
Additional paid-in capital	2,597	1,945	1,442	928	825
Accumulated other comprehensive income	730,000	1	2	852,000	404,000
Accumulated deficit	−1,745	−1,240	−826	−566	−355
Total stockholders equity	853	707	618	362	470
Total liabilities and stockholders equity	957	776	666	406	516

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31
Stock-based compensation	56	49	41	32	34
Depreciation on property and equipment	409,000	377,000	231,000	193,000	126,000
Non-cash lease expense	99,000	133,000	1	1	1
Accounts receivable	986,000	3	−5	12	−12
Prepaid expenses and other current assets	9	−27	2	−21	2
Income tax receivable	−2	−261,000	19,000	461,000	−85,000
Other assets	69,000	−8	0	0	—
Accounts payable	−10	11	6	−17	16
Accrued expenses	45	9	1	16	9
Operating lease liabilities	−99,000	−138,000	−1	−1	−1
Due to Roivant Sciences Ltd.	−98,000	255,000	−329,000	156,000	176,000
Net cash used in operating activities	−407	−376	−214	−188	−106
Purchases of property and equipment	−8,000	−759,000	−360,000	−197,000	−254,000
Net cash used in investing activities	−8,000	−759,000	−360,000	−197,000	−254,000
Proceeds from issuance of common stock upon underwritten offering, net of underwriter discounts and commissions, and private placement	544	450	473	—	—
Payment of offering and private placement costs	−504,000	−319,000	−6	−272,000	0
Proceeds from stock options exercised	52	5	6	657,000	0
Net cash provided by financing activities	596	454	472	71	200
Effect of exchange rate changes on cash and cash equivalents	−299,000	747,000	993,000	220,000	−92,000
Net change in cash and cash equivalents	188	79	259	−117	94
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	73,000	98,000	91,000	0	127,000
Income taxes	2	1	509,000	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Immunovant, Inc.'s CIK number?

Immunovant, Inc.'s SEC CIK number is 0001764013 (1764013). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Immunovant, Inc.'s SEC filings?

All of Immunovant, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Immunovant, Inc. last report earnings?

Immunovant, Inc. (IMVT) most recently filed an earnings 8-K with the SEC on May 20, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001764013-26-000062). This is Immunovant, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Immunovant, Inc.'s most recent earnings 8-K?

Immunovant, Inc.'s latest earnings 8-K (Item 2.02) was filed May 20, 2026 under accession 0001764013-26-000062. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Immunovant, Inc.'s latest earnings 8-K →
Look up any company's CIK number →